170 Middlesex Turnpike
Bedford, MA | 112,000 SF
Ultragenyx Pharmaceutical, Inc. – Groundbreaking Biomanufacturing Facility
In early 2020, the Ultragenyx team met on the side of the road to look at an undeveloped wooded lot to locate what would become their first company-owned biomanufacturing facility. The Gutierrez Company presented the opportunity to deliver a new, fully customizable facility – one that had yet to be designed, permitted, or constructed…and then the COVID pandemic struck.
Nonetheless, the Ultragenyx team, bolstered by our track record of success and strong ties in the Bedford community, engaged The Gutierrez Company to deliver this the new facility for the manufacture of therapies for ultra rare diseases. Within seven months of that roadside meeting, the parties reached a deal. The Gutierrez Company designed the project in collaboration with Ultragenyx. We obtained all permits and shovels hit the ground for a 112,000 square foot facility expandable up to 176,000 square feet. The building shell, constructed through the pandemic winter of 2020/21, was delivered on schedule for interior fit-out work to begin just eight months after construction started.
Following completion of the full manufacturing suite, testing and validation, medicines are now being delivered from this new facility.
Gil Stevens, Executive Director of Global Engineering, Ultragenyx Pharmaceutical, Inc. wrote:
“Thank you for your partnership on this critical project for Ultragenyx. I would recommend TGC as a partner of choice for the development and construction of a new facility. The organization has been professional, experienced and transparent throughout the course of our project. Your staff is knowledgeable in the life sciences sector and adaptable to changing needs and conditions as evidenced by delivering the project on budget and ahead of schedule during the peak of the pandemic. Your collaborative approach allowed for proactive integration of our specific needs and lead to a very successful outcome for all parties.”